Wikipedia

Miriplatin

Miriplatin (INN; trade name Miripla) is a drug used to treat hepatocellular carcinoma (HCC). It is a lipophilic platinum complex that is used in transcatheter arterial chemoembolization (TACE).[1][2] Miriplatin was approved by Japan's Pharmaceuticals and Medical Devices Agency in 2009.[1]

Miriplatin
Clinical data
Trade namesMiripla
Legal status
Legal status
  • Rx in Japan
Identifiers
  • Cyclohexane-(1R,2R)-diamineplatinum(II) dimyristate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC34H68N2O4Pt
Molar mass764.012 g·mol−1
3D model (JSmol)
  • CCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCC(=O)[O-].C1CC[C@]([H])([C@@]([H])(C1)N)N.[Pt+2]
  • InChI=1S/2C14H28O2.C6H14N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;/q;;;+2/p-2/t;;5-,6-;/m..1./s1
  • Key:BGIHRZPJIYJKAZ-BLUNCNMSSA-L

See also

edit

References

edit
  1. ^ a b "Miriplatin". Inxight Drugs. National Center for Advancing Translational Sciences, National Institutes of Health.
  2. ^ Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, et al. (February 2018). "Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial". Journal of Gastroenterology. 53 (2): 281–290. doi:10.1007/s00535-017-1374-6. PMC 5846877. PMID 28766016.
edit
 

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Miriplatin&oldid=1240988924"